Nadofaragene firadenovec, sold under the brand name adstiladrin, is a gene therapy for the treatment of bladder cancer Introduction on december 16, 2022, fda approved nadofaragene firadenovec (brand name adstiladrin), the first gene therapy for the treatment of bladder cancer This medicine is to be used only by or under the direct supervision of a doctor. It delivers a copy of the gene encoding ifnα2b to the bladder urothelium resulting in local expression of the ifnα2b protein for anti. Adstiladrin is a localized gene therapy designed to help the immune system fight nmibc directly within the bladder
OPEN
